0001104659-20-057093.txt : 20200506 0001104659-20-057093.hdr.sgml : 20200506 20200505210234 ACCESSION NUMBER: 0001104659-20-057093 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20200505 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200506 DATE AS OF CHANGE: 20200505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 20850883 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 tm2018740-1_8k.htm FORM 8-K
0001551152 false Common Stock, $0.01 Par Value ABBV 0001551152 2020-05-04 2020-05-05 0001551152 us-gaap:CommonStockMember exch:XNYS 2020-05-04 2020-05-05 0001551152 exch:XCHI us-gaap:CommonStockMember 2020-05-04 2020-05-05 0001551152 abbv:Sec1.375SeniorNotesDue2024Member exch:XNYS 2020-05-04 2020-05-05 0001551152 abbv:Sec0.750SeniorNotesDue2027Member exch:XNYS 2020-05-04 2020-05-05 0001551152 abbv:Sec2.125SeniorNotesDue2028Member exch:XNYS 2020-05-04 2020-05-05 0001551152 abbv:Sec1.250SeniorNotesDue2031Member exch:XNYS 2020-05-04 2020-05-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 5, 2020

 

ABBVIE INC.

 

(Exact Name of Registrant as Specified in its Charter)

_______________________________________________

 

Delaware   001-35565   32-0375147
(State or other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

_______________________________________________

 

1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (847) 932-7900

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange
Chicago Stock Exchange
1.375% Senior Notes due 2024   ABBV24   New York Stock Exchange
0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange
2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange
1.250% Senior Notes due 2031   ABBV31   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

Common Stock, $0.01 Par Value ABBV

 

 

Item 8.01. Other Events.

 

FTC Approval

 

On May 5, 2020, the Federal Trade Commission (“FTC”) accepted a proposed consent order that allows AbbVie Inc.’s (“AbbVie”) pending acquisition (the “Acquisition”) of Allergan plc to proceed, subject to certain conditions.

 

As a result of the FTC’s acceptance of the consent order, all regulatory approvals required for the consummation of the Acquisition have been obtained. 

 

On May 5, 2020, AbbVie issued a press release announcing that all required regulatory approvals necessary to complete the Acquisition have been obtained.  A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety.

 

Other

 

Additionally, AbbVie and Allergan have amended their Transaction Agreement to provide that only one Allergan Director will join the AbbVie board following close.   Allergan’s current Chairman and CEO Brent Saunders has elected not to join the AbbVie Board to provide more flexibility to pursue other opportunities in the sector.

 

Extension of Exchange Offers

 

On May 5, 2020, AbbVie issued a press release (the “Extension Press Release”) announcing that it has extended the expiration date of its previously announced (i) offers to exchange (each, an “Exchange Offer” and, collectively, the “Exchange Offers”) any and all outstanding notes of certain series issued by Allergan Finance, LLC (“Allergan Finance”), Allergan, Inc. (“Allergan Inc”), Allergan Sales, LLC (“Allergan Sales”) and Allergan Funding SCS (“Allergan Funding” and, together with Allergan Finance, Allergan Inc and Allergan Sales, “Allergan”) (the “Allergan Notes”) for new notes to be issued by AbbVie (the “AbbVie Notes”) and (ii) related consent solicitations (each, a “Consent Solicitation” and, collectively, the “Consent Solicitations”) being made by AbbVie on behalf of Allergan to adopt certain amendments (the “Amendments”) to eliminate substantially all of the covenants, restrictive provisions, events of default and any guarantees of the related Allergan Notes in each of the indentures governing the Allergan Notes.

 

AbbVie extended such expiration date from 5:00 p.m., New York City time, on May 8, 2020 to 5:00 p.m., New York City time, on May 12, 2020 (the “Expiration Date”). AbbVie currently expects that there will be no further extensions of the Expiration Date.

 

The Exchange Offers and Consent Solicitations were commenced in connection with the Acquisition and are being made pursuant to the terms and subject to the conditions set forth in the confidential offering memorandum and consent solicitation statement, dated October 25, 2019, and the related letter of transmittal, each as amended by the press releases dated November 18, 2019, December 20, 2019, January 27, 2020, February 24, 2020, March 9, 2020, March 23, 2020, April 6, 2020, April 20, 2020, April 27, 2020 and the attached Extension Press Release. The Exchange Offers and Consent Solicitations are conditioned upon the consummation of the Acquisition, which condition may not be waived by AbbVie, and certain other conditions that may be waived by AbbVie.

 

2

 

 

The settlement date of the Exchange Offers and Consent Solicitations is expected to occur on May 14, 2020.

 

Supplemental indentures effecting the Amendments were executed on November 7, 2019. Such supplemental indentures will become operative only upon settlement of the Exchange Offers.

 

The AbbVie Notes offered in the Exchange Offers have not been registered under the Securities Act of 1933, as amended, or any state securities laws. Therefore, the AbbVie Notes may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933, as amended, and any applicable state securities laws.

 

A copy of the Extension Press Release issued by AbbVie is attached as Exhibit 99.2 hereto and is incorporated by reference herein. 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.		   Exhibit
99.1   Press Release dated May 5, 2020 (Acquisition).
     
99.2   Press Release dated May 5, 2020 (Exchange Offers).
     
104   The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). 

 

3

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABBVIE INC.
   
Date: May 5, 2020 By: /s/ Robert A. Michael
    Robert A. Michael
    Executive Vice President, Chief Financial Officer
     

4

  

 EX-99.1 2 tm2018740d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

PRESS RELEASE

 

AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie’s Acquisition of Allergan

 

NORTH CHICAGO, Ill. and DUBLIN, May 5, 2020  – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Federal Trade Commission (FTC) has accepted the proposed consent order in connection with AbbVie’s pending acquisition of Allergan. The acceptance by the FTC satisfies all required antitrust clearances needed to be obtained for the acquisition of Allergan by AbbVie.

 

As part of the proposed consent, Allergan has agreed to divest brazikumab, an investigational IL-23 inhibitor in development for autoimmune diseases, to AstraZeneca and Zenpep, a treatment for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions, to Nestle. Nestle also will be acquiring Viokace, another pancreatic enzyme preparation, as part of the same transaction.

 

Additionally, AbbVie and Allergan have amended their Transaction Agreement to provide that only one Allergan Director will join the AbbVie board following close. Allergan’s current Chairman and CEO Brent Saunders has elected not to join the AbbVie Board to provide more flexibility to pursue other opportunities in the sector.

 

The closing of the acquisition remains subject to other customary closing conditions set forth in the transaction agreement and Irish High Court approval. A hearing is scheduled for May 6, 2020.

 

About AbbVie

 

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.  In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

 

 

 

 

 

About Allergan plc

 

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

 

With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers, and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

 

For more information, visit Allergan's website at www.Allergan.com.

 

About Zenpep

 

ZENPEP® (pancrelipase) is a prescription medication for people who cannot digest food normally because their pancreas does not make enough enzymes. ZENPEP may help your body use fats, proteins, and sugars from food. ZENPEP contains a mixture of digestive enzymes (lipases, proteases, and amylases) from pig pancreas. In clinical studies, individuals with exocrine pancreatic insufficiency associated with cystic fibrosis absorbed more fat from foods than those treated with a placebo.

 

About Brazikumab

 

Brazikumab is a monoclonal antibody that binds to the IL23 receptor and is in development for Crohn’s Disease and Ulcerative Colitis with a companion biomarker. Brazikumab selectively blocks the IL23 immune signal, preventing intestinal inflammation. The Phase IIb/III INTREPID program is underway to assess brazikumab compared to placebo or adalimumab in Crohn’s Disease. The Phase II EXPEDITION trial is underway to assess brazikumab compared to placebo or vedolizumab in Ulcerative Colitis.

 

 

 

 

 

Forward-Looking Statements

 

This announcement contains certain forward-looking statements, including with respect to the pending acquisition involving AbbVie and Allergan and AbbVie's, Allergan’s and/or the combined group's estimated or anticipated future business, performance and results of operations and financial condition, including estimates, forecasts, targets and plans for AbbVie and, following the acquisition, if completed, the combined group. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the possibility that the pending acquisition will not be pursued, failure to satisfy any of the conditions to the pending acquisition, adverse effects on the market price of AbbVie's shares of common stock or Allergan’s ordinary shares and on AbbVie's or Allergan’s operating results because of a failure to complete the pending acquisition, failure to realize the expected benefits of the pending acquisition, failure to promptly and effectively integrate Allergan's businesses, negative effects relating to the announcement of the pending acquisition or any further announcements relating to the pending acquisition or the consummation of the pending acquisition on the market price of AbbVie’s shares of common stock or Allergan’s ordinary shares, significant transaction costs and/or unknown or inestimable liabilities, potential litigation associated with the pending acquisition, general economic and business conditions that affect the combined companies following the consummation of the pending acquisition, changes in global, political, economic, business, competitive, market and regulatory forces, future exchange and interest rates, changes in tax laws, regulations, rates and policies, future business acquisitions or disposals, competitive developments and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. These forward-looking statements are based on numerous assumptions and assessments made in light of AbbVie's or, as the case may be, Allergan’s experience and perception of historical trends, current conditions, business strategies, operating environment, future developments and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements in this announcement could cause AbbVie’s plans with respect to Allergan or AbbVie’s or Allergan’s actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and persons reading this announcement are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as of the date of this announcement. Additional information about economic, competitive, governmental, technological and other factors that may affect AbbVie or Allergan is set forth in AbbVie’s or Allergan’s periodic public filings with the U.S. Securities and Exchange Commission, including, but not limited to, AbbVie's and Allergan’s Annual Report on Form 10-K for the year ended December 31, 2019 and, from time to time, AbbVie’s and Allergan’s other investor communications, in each case, the contents of which are not incorporated by reference into, nor do they form part of, this announcement.

 

 

 

 

 

Any forward-looking statements in this announcement are based upon information available to AbbVie, Allergan and/or their respective board of directors, as the case may be, as of the date of this announcement and, while believed to be true when made, may ultimately prove to be incorrect. Subject to any obligations under applicable law, none of AbbVie, Allergan or any member of their respective board of directors undertakes any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. All subsequent written and oral forward-looking statements attributable to AbbVie, Allergan or their respective board of directors or any person acting on behalf any of them are expressly qualified in their entirety by this paragraph.

 

Statement Required by Irish Takeover Rules

 

The directors of AbbVie Inc. accept responsibility for the information contained in this announcement other than that relating to Allergan plc and its subsidiaries and/or the directors of Allergan and members of their immediate families, related trusts, and persons connected with them. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement for which they accept responsibility is  in accordance with the facts and does not omit anything likely to affect the import of such information.

 

The directors of Allergan accept responsibility for the information contained in this announcement relating to Allergan and its subsidiaries and/or the directors of Allergan and members of their immediate families, related trusts, and persons connected with them. To the best of the knowledge and belief of the Allergan directors (who have taken all reasonable care to ensure such is the case), the information contained in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

 

Any holder of 1% or more of any class of relevant securities of Allergan plc or AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

 

###

 

Media: Investors:
Adelle Infante Liz Shea
(847) 938-8745 (847) 935-2211

 

 

 

 EX-99.2 3 tm2018740d1_ex99-2.htm EXHIBIT 99.2

 

Exhibit 99.2

 

 

AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes and Expects No Further Extensions of Expiration Date

 

NORTH CHICAGO, Ill., May 5, 2020 – AbbVie Inc. (NYSE:ABBV) (“AbbVie”) announced today the extension of the expiration date of the offers to exchange (each, an “Exchange Offer” and, collectively, the “Exchange Offers”) any and all outstanding notes of certain series issued by Allergan Finance, LLC (“Allergan Finance”), Allergan, Inc. (“Allergan Inc”), Allergan Sales, LLC (“Allergan Sales”) and Allergan Funding SCS (“Allergan Funding” and, together with Allergan Finance, Allergan Inc and Allergan Sales, “Allergan”) (the “Allergan Notes”) for new notes to be issued by AbbVie (the “AbbVie Notes”) and the related consent solicitations (each, a “Consent Solicitation” and, collectively, the “Consent Solicitations”) being made by AbbVie on behalf of Allergan to adopt certain amendments to each of the indentures (each, an “Allergan Indenture”) governing the Allergan Notes. AbbVie hereby extends such expiration date from 5:00 p.m., New York City time, on May 8, 2020 to 5:00 p.m., New York City time, on May 12, 2020 (the “Expiration Date”). AbbVie currently expects that there will be no further extensions of the Expiration Date.

 

On the early participation date of November 7, 2019, requisite consents were received and supplemental indentures were executed eliminating substantially all of the covenants, restrictive provisions, events of default and any guarantees of the related Allergan Notes in each Allergan Indenture. Such supplemental indentures will become operative only upon settlement of the Exchange Offers, which is expected to occur on May 14, 2020.

 

The Exchange Offers and Consent Solicitations were commenced in connection with AbbVie’s previously announced proposed acquisition of Allergan plc (the “Acquisition”) and are being made pursuant to the terms and subject to the conditions set forth in the confidential offering memorandum and consent solicitation statement, dated October 25, 2019, and the related letter of transmittal, each as amended by the press releases dated November 18, 2019, December 20, 2019, January 27, 2020, February 24, 2020, March 9, 2020, March 23, 2020, April 6, 2020, April 20, 2020 and April 27, 2020 and as amended hereby (collectively, the “Offering Documents”), and are conditioned upon the closing of the Acquisition, which condition may not be waived by AbbVie, and certain other conditions that may be waived by AbbVie.

 

Except as described in this press release, all other terms of the Exchange Offers and Consent Solicitations remain unchanged.

 

As of 5:00 p.m., New York City time, on May 5, 2020, the principal amounts of Allergan Notes set forth in the table below were validly tendered and not validly withdrawn:

 

1

 

 

   Allergan Notes Tendered as of 5:00
p.m., New York City time, May 5, 2020		 
Title of Series of
Notes		  CUSIP /
ISIN No.		  Issuer  Principal Amount
Outstanding		   Principal Amount   Percentage 
3.375% Senior Notes due 2020  018490AN2  Allergan, Inc.  $650,000,000   $296,421,000    45.60%
4.875% Senior Notes due 2021  345838AE6 (144A) / U3455QAC7
(Reg S)		  Allergan Sales, LLC  $450,000,000   $419,727,000    93.27%
5.000% Senior Notes due 2021  345838AA4 (144A) / U3455QAA1
(Reg S)		  Allergan Sales, LLC  $1,200,000,000   $1,048,624,000    87.39%
3.450% Senior Notes due 2022  00507UAR2  Allergan Funding SCS  $2,878,224,000   $2,366,962,000    82.24%
3.250% Senior Notes due 2022  942683AF0  Allergan Finance, LLC  $1,700,000,000   $1,364,125,000    80.24%
2.800% Senior Notes due 2023  018490AQ5  Allergan, Inc.  $350,000,000   $226,427,000    64.69%
3.850% Senior Notes due 2024  00507UAF8  Allergan Funding SCS  $1,036,740,000   $919,374,000    88.68%
3.800% Senior Notes due 2025  00507UAS0  Allergan Funding SCS  $3,020,692,000   $2,670,938,000    88.42%
4.550% Senior Notes due 2035  00507UAT8  Allergan Funding SCS  $1,789,000,000   $1,438,045,000    80.38%
4.625% Senior Notes due 2042  942683AH6  Allergan Finance, LLC  $456,710,000   $373,005,000    81.67%
4.850% Senior Notes due 2044  00507UAH4  Allergan Funding SCS  $1,079,360,000   $815,786,000    75.58%
4.750% Senior Notes due 2045  00507UAU5  Allergan Funding SCS  $880,956,000   $752,373,000    85.40%
Floating Rate Notes due 2020  XS1909193077  Allergan Funding SCS  €700,000,000   €542,653,000    77.52%
0.500% Senior Notes due 2021  XS1622630132  Allergan Funding SCS  €750,000,000   €497,221,000    66.30%
1.500% Senior Notes due 2023  XS1909193150  Allergan Funding SCS  €500,000,000   €406,990,000    81.40%
1.250% Senior Notes due 2024  XS1622624242  Allergan Funding SCS  €700,000,000   €587,714,000    83.96%
2.625% Senior Notes due 2028  XS1909193317  Allergan Funding SCS  €500,000,000   €418,977,000    83.80%
2.125% Senior Notes due 2029  XS1622621222  Allergan Funding SCS  €550,000,000   €506,045,000    92.01%

 

Documents relating to the Exchange Offers and Consent Solicitations will only be distributed to eligible holders of Allergan Notes who complete and return an eligibility form confirming that they are either a “qualified institutional buyer” as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), or not a “U.S. person” and outside the United States within the meaning of Regulation S under the Securities Act. Except as amended by the press releases dated November 18, 2019, December 20, 2019, January 27, 2020, February 24, 2020, March 9, 2020, March 23, 2020, April 6, 2020, April 20, 2020 and April 27, 2020 and as amended hereby, the complete terms and conditions of the Exchange Offers and Consent Solicitations are described in the Offering Documents, copies of which may be obtained by contacting Global Bondholder Services Corporation, the exchange agent and information agent in connection with the Exchange Offers and Consent Solicitations, at (866) 470-3900 (U.S. toll-free) or (212) 430-3774 (banks and brokers). The eligibility form is available electronically at: https://gbsc-usa.com/eligibility/abbvie.

 

2

 

 

This news release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders or consents with respect to, any security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation or sale would be unlawful. The Exchange Offers and Consent Solicitations are being made solely pursuant to the Offering Documents and only to such persons and in such jurisdictions as are permitted under applicable law.

 

The AbbVie Notes offered in the Exchange Offers have not been registered under the Securities Act or any state securities laws. Therefore, the AbbVie Notes may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and any applicable state securities laws.

 

Cautionary Statement Regarding Forward-Looking Information

 

This news release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including forward-looking statements with respect to the Acquisition and/or the combined group’s estimated or anticipated future business, performance and results of operations and financial condition, including estimates, forecasts, targets and plans for AbbVie and, following the Acquisition, if consummated, the combined group, as well as the expected timing of completion of the Exchange Offers. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the failure to satisfy any of the conditions to the Acquisition, adverse effects on the market price of AbbVie’s shares of common stock and operating results because of a failure to consummate the Acquisition, failure to realize the expected benefits of the Acquisition, failure to promptly and effectively integrate Allergan plc’s businesses, significant transaction costs and/or unknown or inestimable liabilities, potential litigation associated with the Acquisition, the combined company’s capital structure post-Acquisition, the nature of any debt issued to fund the Acquisition and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. These forward-looking statements are based on numerous assumptions and assessments made in light of AbbVie’s experience and perception of historical trends, current conditions, business strategies, operating environment, future developments and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements in this news release could cause AbbVie’s plans with respect to Allergan plc or AbbVie’s actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and persons reading this news release are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this news release. Additional information about economic, competitive, governmental, technological and other factors that may affect AbbVie can be found in AbbVie’s filings with the SEC, including the risk factors discussed in AbbVie’s most recent Annual Report on Form 10-K, as updated by its future filings with the SEC.

 

3

 

 

Any forward-looking statements in this news release are based upon information available to AbbVie as of the date of this news release and, while believed to be true when made, may ultimately prove to be incorrect. Subject to any obligations under applicable law, AbbVie undertakes no obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. All subsequent written and oral forward-looking statements attributable to AbbVie or any person acting on their behalf are expressly qualified in their entirety by this paragraph.

 

Contacts

 

Media

Adelle Infante

847-938-8745

adelle.infante@abbvie.com

 

or

 

Investors

Liz Shea

847-935-2211

liz.shea@abbvie.com

 

4

 

 EX-101.SCH 4 abbv-20200505.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 abbv-20200505_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 abbv-20200505_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] Entity Listings, Exchange [Axis] NEW YORK STOCK EXCHANGE, INC. [Member] CHICAGO STOCK EXCHANGE, INC [Member] Sec 1.375 Senior Notes Due 2024 [Member] Sec 0.750 Senior Notes Due 2027 [Member] Sec 2.125 Senior Notes Due 2028 [Member] Sec 1.250 Senior Notes Due 2031 [Member] Entity Listings [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Sec 1.375 Senior Notes Due 2024 [Member] Sec 0.750 Senior Notes Due 2027 [Member] Sec 2.125 Senior Notes Due 2028 [Member] Sec 1.250 Senior Notes Due 2031 [Member] EX-101.PRE 7 abbv-20200505_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 tm2018740d1_ex99-1img001.jpg GRAPHIC begin 644 tm2018740d1_ex99-1img001.jpg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end GRAPHIC 9 tm2018740d1_ex99-1img002.jpg GRAPHIC begin 644 tm2018740d1_ex99-1img002.jpg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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover
May 05, 2020
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 05, 2020
Entity File Number 001-35565
Entity Registrant Name ABBVIE INC.
Entity Central Index Key 0001551152
Entity Tax Identification Number 32-0375147
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1 North Waukegan Road
Entity Address, City or Town North Chicago
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60064-6400
City Area Code 847
Local Phone Number 932-7900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, $0.01 Par Value
Trading Symbol ABBV
Security Exchange Name NYSE
Common Stock [Member] | CHICAGO STOCK EXCHANGE, INC [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, $0.01 Par Value
Trading Symbol ABBV
Security Exchange Name CHX
Sec 1.375 Senior Notes Due 2024 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 1.375% Senior Notes due 2024
Trading Symbol ABBV24
Security Exchange Name NYSE
Sec 0.750 Senior Notes Due 2027 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 0.750% Senior Notes due 2027
Trading Symbol ABBV27
Security Exchange Name NYSE
Sec 2.125 Senior Notes Due 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 2.125% Senior Notes due 2028
Trading Symbol ABBV28
Security Exchange Name NYSE
Sec 1.250 Senior Notes Due 2031 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 1.250% Senior Notes due 2031
Trading Symbol ABBV31
Security Exchange Name NYSE
XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 7 95 1 false 7 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://abbvie.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2018740-1_8k.htm abbv-20200505.xsd abbv-20200505_def.xml abbv-20200505_lab.xml abbv-20200505_pre.xml tm2018740d1_ex99-1.htm tm2018740d1_ex99-2.htm http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://xbrl.sec.gov/exch/2019-01-31 true false XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2018740-1_8k.htm": { "axisCustom": 0, "axisStandard": 2, "contextCount": 7, "dts": { "definitionLink": { "local": [ "abbv-20200505_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "tm2018740-1_8k.htm" ] }, "labelLink": { "local": [ "abbv-20200505_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "abbv-20200505_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "abbv-20200505.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 72, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 4, "memberStandard": 3, "nsprefix": "abbv", "nsuri": "http://abbvie.com/20200505", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm2018740-1_8k.htm", "contextRef": "From2020-05-04to2020-05-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://abbvie.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm2018740-1_8k.htm", "contextRef": "From2020-05-04to2020-05-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 7, "tag": { "abbv_Sec0.750SeniorNotesDue2027Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sec 0.750 Senior Notes Due 2027 [Member]", "label": "Sec 0.750 Senior Notes Due 2027 [Member]" } } }, "localname": "Sec0.750SeniorNotesDue2027Member", "nsuri": "http://abbvie.com/20200505", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "abbv_Sec1.250SeniorNotesDue2031Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sec 1.250 Senior Notes Due 2031 [Member]", "label": "Sec 1.250 Senior Notes Due 2031 [Member]" } } }, "localname": "Sec1.250SeniorNotesDue2031Member", "nsuri": "http://abbvie.com/20200505", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "abbv_Sec1.375SeniorNotesDue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sec 1.375 Senior Notes Due 2024 [Member]", "label": "Sec 1.375 Senior Notes Due 2024 [Member]" } } }, "localname": "Sec1.375SeniorNotesDue2024Member", "nsuri": "http://abbvie.com/20200505", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "abbv_Sec2.125SeniorNotesDue2028Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sec 2.125 Senior Notes Due 2028 [Member]", "label": "Sec 2.125 Senior Notes Due 2028 [Member]" } } }, "localname": "Sec2.125SeniorNotesDue2028Member", "nsuri": "http://abbvie.com/20200505", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHICAGO STOCK EXCHANGE, INC [Member]" } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } XML 18 tm2018740-1_8k_htm.xml IDEA: XBRL DOCUMENT 0001551152 2020-05-04 2020-05-05 0001551152 us-gaap:CommonStockMember exch:XNYS 2020-05-04 2020-05-05 0001551152 us-gaap:CommonStockMember exch:XCHI 2020-05-04 2020-05-05 0001551152 abbv:Sec1.375SeniorNotesDue2024Member exch:XNYS 2020-05-04 2020-05-05 0001551152 abbv:Sec0.750SeniorNotesDue2027Member exch:XNYS 2020-05-04 2020-05-05 0001551152 abbv:Sec2.125SeniorNotesDue2028Member exch:XNYS 2020-05-04 2020-05-05 0001551152 abbv:Sec1.250SeniorNotesDue2031Member exch:XNYS 2020-05-04 2020-05-05 iso4217:USD shares iso4217:USD shares 0001551152 false Common Stock, $0.01 Par Value ABBV 8-K 2020-05-05 ABBVIE INC. DE 001-35565 32-0375147 1 North Waukegan Road North Chicago IL 60064-6400 847 932-7900 false false false false Common Stock, $0.01 Par Value ABBV NYSE CHX 1.375% Senior Notes due 2024 ABBV24 NYSE 0.750% Senior Notes due 2027 ABBV27 NYSE 2.125% Senior Notes due 2028 ABBV28 NYSE 1.250% Senior Notes due 2031 ABBV31 NYSE false ZIP 19 0001104659-20-057093-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-057093-xbrl.zip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